Unlock instant, AI-driven research and patent intelligence for your innovation.

Application of recombinant human fibroblast growth factor 7 mutant in preparing medicament for treating cervical erosion

A technology of human fibroblasts and growth factors, applied in drug combinations, medical preparations containing active ingredients, pharmaceutical formulas, etc., can solve problems such as the application of cervical erosion without FGF7 mutants

Active Publication Date: 2010-06-09
信立泰(苏州)药业有限公司
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is currently no therapeutic application of FGF7 mutants for cervical erosion

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of recombinant human fibroblast growth factor 7 mutant in preparing medicament for treating cervical erosion

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0016] The preparation of embodiment 1 freeze-dried preparation of the present invention

[0017] Active ingredient: recombinant human fibroblast growth factor 7 mutant (you can buy the product palifermin or kepivance from Amgen, USA) or use conventional gene recombination technology to produce recombinant human fibroblast growth factor 7 mutant, the method is as follows:

[0018] a. According to methods well known to those skilled in the field of biotechnology, artificially synthesize or use RT-PCR technology to clone the cDNA sequence of recombinant human fibroblast growth factor 7 mutant [Fibroblast growth factor 7, Homo sapiens, GeneID 2252], and construct a recombinant plasmid , and transfect engineering bacteria E.coli to express, to obtain genetically engineered bacteria expressing recombinant human fibroblast growth factor 7 mutants, and to produce recombinant human fibroblast growth factor 7 mutants by fermenting and cultivating genetically engineered bacteria;

[001...

Embodiment 2

[0022] The preparation of embodiment 2 spray formulations of the present invention

[0023] In order to facilitate transportation and storage, recombinant human fibroblast growth factor 7 mutants are prepared into freeze-dried preparations, which can be prepared as spray preparations according to needs when used: dissolve the freeze-dried preparations with normal saline or common medical solvents, and the activity after dissolution The substance concentration ranges from 500ng to 50ug / ml, put it into a sprayer that meets the requirements, and then spray it for use.

Embodiment 3

[0024] The preparation of embodiment 3 gel formulations of the present invention

[0025] In order to facilitate transportation and storage, recombinant human fibroblast growth factor 7 mutants are prepared into freeze-dried preparations, which can be formulated into gel preparations according to needs during use. The preparation method is as follows:

[0026] Using polyoxyethylene-polyoxypropylene block copolymer (Pluronic) as a liquid at low temperature, and condensed into a gel at body temperature, it is prepared as a gel companion of recombinant human fibroblast growth factor 7 freeze-dried powder, which is compatible with human Fibroblast growth factor 7 freeze-dried powder is stored together at low temperature (4-8°C). When used, dissolve the freeze-dried powder with a gel companion, suck it out and apply it to the affected area. The body temperature will form a gel to cover the affected area and release human fibroblasts. Growth factor 7 mutants produce therapeutic effe...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a new application of recombinant human fibroblast growth factor 7 mutant in treating cervical erosion of women. In the invention, the specificity of the recombinant human fibroblast growth factor 7 mutant is used for promoting the biological activity of epithelial cell proliferation and improving the stability, and the recombinant protein applied in focus sites can promotethe repair of mucous epithelium damage, promote structure repair of cervical erosion sites, and achieve the effect of treating the cervical erosion.

Description

technical field [0001] The invention relates to a new application of recombinant human fibroblast growth factor 7 mutant, especially the application in the preparation of medicine for treating women's cervical erosion. Specifically, the recombinant human fibroblast growth factor 7 mutant is prepared into a preparation that can maintain its biological activity and is suitable for vaginal administration, and the vaginal administration is used to treat women's cervical erosion. Background technique [0002] Cervical erosion is a common gynecological disease, mostly developed from acute and chronic cervicitis without effective treatment. Cervical erosion has a high incidence rate among sexually active women, most of which are caused by sexual life, equipment damage, excessive cleaning or cervical injury during childbirth, and also caused by menstrual infection due to weak constitution. The total incidence rate reaches 26%- 52% are diseases that seriously threaten women's health...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/18A61P15/00
Inventor 赵斌彭红卫杨伟张宝华董佳里
Owner 信立泰(苏州)药业有限公司